Epidemiology of tuberculosis and HIV: Recent advances in understanding and responses

Proceedings of the American Thoracic Society

Volumn 8, Issue 3, 2011, Pages 288-293

  Martinson, Neil A ^a,b   Hoffmann, Christopher J ^a,b   Chaisson, Richard E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiretroviral therapy; Intensified case finding; Preventive treatment; Xpert MTB rif

Indexed keywords

ANTIRETROVIRUS AGENT; BEDAQUILINE; COTRIMOXAZOLE; ISONIAZID;

ANTIVIRAL THERAPY; CAUSE OF DEATH; COMMUNITY CARE; CONFERENCE PAPER; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; LUNG TUBERCULOSIS; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; INFECTION CONTROL; ISONIAZID; LIPOPOLYSACCHARIDES; POLYMERASE CHAIN REACTION; REAGENT STRIPS; RISK FACTORS; SPUTUM; TUBERCULOSIS;

EID: 80051721079     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201010-064WR     Document Type: Conference Paper

References (84)

1. Macpherson P., Moshabela M., Martinson N., Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 2009;103:588-593
2. Etard J.F., Ndiaye I., Thierry-Mieg M., Gueye N.F., Gueye P.M., Laniece I., Dieng A.B., Diouf A., Laurent C., Mboup S., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006;20:1181-1189. (Pubitemid 43786107)
3. Brinkhof M.W., Egger M., Boulle A., May M., Hosseinipour M., Sprinz E., Braitstein P., Dabis F., Reiss P., Bangsberg D.R., et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45:1518-1521. (Pubitemid 351411886)
4. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva, Switzerland: World Health Organization; 2009.
5. World Health Organization. Global tuberculosis control: WHO Report Geneva, Switzerland; World Health Organization: 2010.
6. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva, Switzerland: World Health Organization; 2009.
7. Statistics South Africa. Mortality and causes of death in South Africa: findings from death notification. Pretoria, South Africa: Statistics South Africa; 2009.
8. Reddy E.A., Shaw A.V., Crump J.A. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:417-432.
9. Hanrahan C.F., Golub J.E., Mohapi L., Tshabangu N., Modisenyane T., Chaisson R.E., Gray G.E., McIntyre J.A., Martinson N.A. Body mass index and risk of tuberculosis and death. AIDS 2010;24:1501-1508.
10. Martinson N.A., Pronyk P., Chaisson R.E., Moshabela M., Tshabangu N., de Bruyn G., Nayagar S., Gray G.E., McIntyre J.A., Pronyk P TB risk and smoking in HIV-infected adults: a prospective cohort Abstract# 998. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008, Boston, MA. Abstract 998.
11. Lawn S.D., Myer L., Edwards D., Bekker L.G., Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-1725.
12. Antonucci G., Girardi E., Raviglione M.C., Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995;274:143-148.
13. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? a retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150-158. (Pubitemid 40096371)
14. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003;188:1146-1155. (Pubitemid 37338979)
15. Corbett E.L., Churchyard G.J., Clayton T.C., Williams B.G., Mulder D., Hayes R.J., De Cock K.M. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000;14:2759-2768. (Pubitemid 32118730)
16. Corbett E.L., Charalambous S., Fielding K., Clayton T., Hayes R.J., De Cock K.M., Churchyard G.J. Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis 2003;188:1156-1163. (Pubitemid 37338980)
17. Bateman C. The protracted TB struggle: SA ups the intensity. S Afr Med J 2010;100:207-209.
18. Hanifa Y., Grant A.D., Lewis J., Corbett E.L., Fielding K., Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009;13:39-46.
19. Park H.H., Girdler-Brown B.V., Churchyard G.J., White N.W., Ehrlich R.I. Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners. Am J Ind Med 2009;52:901-908.
20. Meel B.L. Patterns of lung diseases in former mine workers of the former Republic of the Transkei: an X-ray-based study. Int J Occup Environ Health 2002;8:105-110. (Pubitemid 34465282)
21. Girdler-Brown B.V., White N.W., Ehrlich R.I., Churchyard G.J. The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. Am J Ind Med 2008;51:640-647.
22. Lockman S., Tappero J.W., Kenyon T.A., Rumisha D., Huebner R.E., Binkin N.J. Tuberculin reactivity in a pediatric population with high BCG vaccination coverage. Int J Tuberc Lung Dis 1999;3:23-30. (Pubitemid 29136557)
23. Basu S., Stuckler D., Gonsalves G., Lurie M. The production of consumption: addressing the impact of mineral mining on tuberculosis in southern Africa. Global Health 2009;5:11.
24. Escombe A.R., Oeser C., Gilman R.H., Navincopa M., Ticona E.,Martinez C., Caviedes L., Sheen P., Gonzalez A., Noakes C., et al. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 2007;44:1349-1357. (Pubitemid 46717298)
25. Talbot E.A., Kenyon T.A., Moeti T.L., Hsin G., Dooley L., El-Halabi S., Binkin N.J. HIV risk factors among patients with tuberculosis - Botswana 1999. Int J STD AIDS 2002;13:311-317. (Pubitemid 34492966)
26. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., Shearer S. HIV and pulmonary tuberculosis: the impact goes beyond those infected with HIV. AIDS 2004;18:657-662. (Pubitemid 38393465)
27. Corbett E.L., Charalambous S., Moloi V.M., Fielding K., Grant A.D., Dye C., De Cock K.M., Hayes R.J., Williams B.G., Churchyard G.J. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004;170:673-679. (Pubitemid 39202210)
28. Corbett E.L., Bandason T., Cheung Y.B., Munyati S., Godfrey-Faussett P., Hayes R., Churchyard G., Butterworth A., Mason P. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007;4:e22.
29. Shapiro A., Rakgokong M., Chaisson R., Modiba P., Msandiwa R., Golub J.E., Variava E., Martinson NA Targeting at-risk households: intensified case finding for TB and HIV in contacts of TB patients in South Africa Presented at the XVIII International AIDS Conference July 18-23, 2010, Vienna, Austria. Abstract FRLBC106.
30. Wood R., Liang H., Wu H., Middelkoop K., Oni T., Rangaka M.X., Wilkinson R.J., Bekker L.G., Lawn S.D. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 2010;14:406-412.
31. Hesseling A.C., Cotton M.F., Jennings T., Whitelaw A., Johnson L.F., Eley B., Roux P., Godfrey-Faussett P., Schaaf H.S. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009;48:108-114.
32. Martinson N.A., Karstaedt A., Venter W.D., Omar T., King P., Mbengo T., Marais E., McIntyre J., Chaisson R.E., Hale M. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007;21:2043-2050. (Pubitemid 47462153)
33. Lucas S.B., Hounnou A., Peacock C., Beaumel A., Djomand G., N'Gbichi J.M., Yeboue K., Honde M., Diomande M., Giordano C., et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993;7:1569-1579. (Pubitemid 24008849)
34. Ansari N.A., Kombe A.H., Kenyon T.A., Hone N.M., Tappero J.W., Nyirenda S.T., Binkin N.J., Lucas S.B., et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002;6:55-63. (Pubitemid 34263546)
35. World Health Organization. WHO three I's meeting. Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and TB Infection Control (IC) for people living with HIV. Report of a joint World Health OrganIzation HIV/AIDS and TB Department meeting. April 2-4, 2008, Geneva, Switzerland.
36. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
37. Akolo C., Adetifa I., Shepperd S., Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;CD000171.
38. Comstock G.W., Baum C., Snider D.E. Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-830.
39. QuigleyM.A., Mwinga A., Hosp M., Lisse I., Fuchs D., Porter J.D.H., Godfrey-Faussett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-222. (Pubitemid 32142297)
40. Johnson J.L., Okwera A., Hom D.L., Mayanja H., Mutuluuza Kityo C., Nsubuga P., Nakibali J.G., Loughlin A.M., Yun H., Mugyenyi P.N., et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-2147. (Pubitemid 33101821)
41. Pape J.W., Jean S.S., Ho J.L., Hafner A., Johnson W.D. Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272. (Pubitemid 23224420)
42. Samandari T The Botswana IPT trial 36 months versus 6 months of isoniazid for TB prevention in HIV infected adults Presented at the 40th Union World Conference on Lung Health, December 3-9, 2009, Cancun, Mexico.
43. Martinson N., Barnes G., Msandiwa R., Moulton L., Gray G., McIntyre J., Hausler H., Ram M., Chaisson R Novel regimens for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trial Presented at the 16th Conference on Retroviruses and Opportunistic Infections February 8-11, 2009, Montreal, Canada. Abstract 36bLB.
44. Swaminathan S., Menon P., Perumal V Efficacy of a 6-month vs a 36-month regimen for prevention of TB in HIV-infected persons in India: a randomized clinical trial Presented at the 17th Conference on Retrovirsuses and Opportunistic Infections February 16-19, 2010, Montreal, Canada Abstract103.
45. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580. (Pubitemid 44780738)
46. O'Donnell M.R., Jarand J., Loveday M., Padayatchi N., Zelnick J., Werner L., Naidoo K., Master I., Osburn G., Kvasnovsky C., et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010;153:516-522.
47. Scano F. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva, Switzerland: World Health Oganization; 2009.
48. Corbett E.L., Bandason T., Duong T., Dauya E., Makamure B., Churchyard G.J., Williams B.G., Munyati S.S., Butterworth A.E., Mason P.R., et al. Comparison of two active case-finding strategies for communitybased diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet 2010;376:1244-1253.
49. Lawn S.D., Wood R., De Cock K.M., Kranzer K., Lewis J.J., Churchyard G.J. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010;10:489-498.
50. Lawn S.D., Badri M., Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116. (Pubitemid 41668999)
51. Etard J.F., Diouf A., De Beaudrap P., Akoi K., Ngom-Gueye N.F., Ndiaye I., Ecochard R., Sow P.S., Eric D. Short and long-term incidence of tuberculosis and CD4-cell count dynamic on HAART in Senegal. Open AIDS J 2009;3:63-70.
52. Edmonds A., Lusiama J., Napravnik S., Kitetele F., Van Rie A., Behets F. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009;38:1612-1621.
53. Martinson N.A., Moultrie H., van Niekerk R., Barry G., Coovadia A., Cotton M., Violari A., Gray G.E., Chaisson R.E., McIntyre J.A., et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009;13:862-867.
54. Middelkoop K., Bekker L.G., Myer L., Whitelaw A., Grant A., Kaplan G., McIntyre J., Wood R. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010;182:1080-1085.
55. Golub J.E., Saraceni V., Cavalcante S.C., Pacheco A.G., Moulton L.H., King B.S., Efron A., Moore R.D., Chaisson R.E., Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-1448. (Pubitemid 46988004)
56. Golub J.E., Pronyk P., Mohapi L., et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-636.
57. Golub J.E., Chaisson R.E., Martinson N.A., Thsabangu N., Moshabela M., Struthers H., Gray G.E., McIntyre J.A., Chaisson R.E., Martinson N.A. Additive effects of isoniazid preventive therapy and HAART. AIDS 2009;23:1446-1447.
58. Innes C., Charalambous S., Felix M., Fielding K., Grant A., Churchyard G Effectiveness of isoniazid preventive therapy in reducing mortality in patients on ART Presented at the 17th Conference on Retroviruses and Opportunistic Infections February16-19 2010, San Francisco, CA. Abstract 102.
59. Lawn S.D., Kranzer K., Edwards D.J., McNally M., Bekker L.G., Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010;24:1323-1328.
60. Meintjes G., Wilkinson R.J., Morroni C., Pepper D.J., Rebe K., Rangaka M.X., Oni T., Maartens G. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24:2381-2390.
61. Harries A.D., Hargreaves N.J., Gausi F., Kwanjana J.H., Salaniponi F.M. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001;5:1000-1005. (Pubitemid 33134749)
62. Edginton M.E., Wong M.L., Phofa R., Mahlaba D., Hodkinson H.J. Tuberculosis at Chris Hani Baragwanath Hospital: numbers of patients diagnosed and outcomes of referrals to district clinics. Int J Tuberc Lung Dis 2005;9:398-402. (Pubitemid 40524030)
63. Alvarez G.G., Thembela B.L.,Muller F.J., Clinch J., Singhal N., CameronD.W. Tuberculosis at Edendale Hospital in Pietermaritzburg, Kwazulu Natal, South Africa. Int J Tuberc Lung Dis 2004;8:1472-1478. (Pubitemid 40070254)
64. Cohen T., Murray M., Wallengren K., Alvarez G.G., Samuel E.Y., Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010;7:e1000296.
65. Wong E.B., Omar T., Stlhako G., Osih R., Murdoch D., Martinson N., Feldman C., Bangsberg D., Venter WDF Causes of death in ARTtreated adults: a post mortem study from Johannesburg Presented at the XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria. Abstract WEPE0154.
66. Gandhi N.R., Shah N.S., Andrews J.R., Vella V., Moll A.P., Scott M., Weissman D., Marra C., Lalloo U.G., Friedland G.H. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-86.
67. Dheda K., Shean K., Zumla A., Badri M., Streicher E.M., Page-Shipp L., Willcox P., John M.A., Reubenson G., Govindasamy D., et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-1807.
68. Wiktor S.Z., Sassan-Morokro M., Grant A.D., Abouya L., Karon J.M., Maurice C., Djomand G., Ackah A., Domoua K., Kadio A., et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-1475. (Pubitemid 29204364)
69. Nunn A.J., Mwaba P., Chintu C., Mwinga A., Darbyshire J.H., Zumla A. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008;337:a257.
70. Hoffmann C.J., Fielding K.L., Charalambous S., Innes C., Chaisson R.E., Grant A.D., Churchyard G.J. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 2010;24:1709-1716.
71. Abdool Karim S.S., Naidoo K., Grobler A., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
72. Blanc F.X., Sok T., Laureillard D., Blanc F.X., Sok T., Laureillard D., Borand L., Rekacewicz C., Nerrienet C., Madec Y., Marcy O., Chan S., Prak N., et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Presented at the XVIII International AIDS Conference. July 18-23, 2010, Vienna, Austria Abstract THLBB106.
73. Chamie G., Charlebois E.D., Srikantiah P., Walusimbi-Nanteza M., Mugerwa R.D., Mayanja H., Okwera A., Whalen C.C., Havlir D.V. Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis 2010;51:359-362.
74. Johnson J.L., Vjecha M.J., Okwera A., Hatanga E., Byekwaso F., Wolski K., Aisu T., Whalen C.C., Huebner R., Mugerwa R.D., et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 1998;2:397-404. (Pubitemid 28239862)
75. Elliott A.M., Namaambo K., Allen B.W., Luo N., Hayes R.J., Pobee J.O., McAdam K.P. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis 1993;74:191-194. (Pubitemid 23188682)
76. Wood R., Middelkoop K., Myer L., Grant A.D., Whitelaw A., Lawn S.D., Kaplan G., Huebner R., McIntyre J., Bekker L.G. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007;175:87-93. (Pubitemid 46105314)
77. Swaminathan S., Paramasivan C.N., Kumar S.R., Mohan V., Venkatesan P. Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis 2004;8:896-898. (Pubitemid 38937608)
78. Agizew T.B., Arwady M.A., Yoon J.C., Nyirenda S., Mosimaneotsile B., Tedla Z., Motsamai O., Kilmarx P.H., Wells C.D., Samandari T. Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. Int J Tuberc Lung Dis 2010;14:45-51.
79. Cain K.P., McCarthy K.D., Heilig C.M., Monkongdee P., Tasaneeyapan T., Kanara N., Kimerling M.E., Chheng P., Thai S., Sar B., et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010;362:707-716.
80. Boehme C.C., Nabeta P., Hillemann D., Nicol M.P., Shenai S., Krapp F., Allen J., Tahirli R., Blakemore R., Rustomjee R., et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-1015.
81. Shah M., Martinson N.A., Chaisson R.E., Martin D.J., Variava E., Dorman S.E. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010;48:2972-2974.
82. Lawn S.D., Edwards D.J., Kranzer K., Vogt M., Bekker L.G., Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009;23:1875-1880.
83. Nuermberger E.L., Spigelman M.K., Yew W.W. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15:764-778.
84. Ma Z., Lienhardt C., McIlleron H., Nunn A.J., Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100-2109.